[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201071421A1 - Анти-flt3 антитела - Google Patents

Анти-flt3 антитела

Info

Publication number
EA201071421A1
EA201071421A1 EA201071421A EA201071421A EA201071421A1 EA 201071421 A1 EA201071421 A1 EA 201071421A1 EA 201071421 A EA201071421 A EA 201071421A EA 201071421 A EA201071421 A EA 201071421A EA 201071421 A1 EA201071421 A1 EA 201071421A1
Authority
EA
Eurasian Patent Office
Prior art keywords
present
flt3 antibodies
flt3
administering
antibodies
Prior art date
Application number
EA201071421A
Other languages
English (en)
Inventor
Ивэнь Ли
Дэн Лу
Дэвид Сургуладзе
Джеймс Р. Тонра
Original Assignee
Имклоун Элэлси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41092183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201071421(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Имклоун Элэлси filed Critical Имклоун Элэлси
Publication of EA201071421A1 publication Critical patent/EA201071421A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Согласно настоящему изобретению предложены полностью человеческие антитела, которые специфично связываются с FLT3 человека в пределах внеклеточных доменов 4 или 5 с высокой аффинностью. Согласно настоящему изобретению также предложены способы лечения лейкоза путем введения эффективного количества указанного антитела отдельно или в комбинации с противораковым средством или лечением, включая метотрексат.
EA201071421A 2008-05-30 2009-05-28 Анти-flt3 антитела EA201071421A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13039508P 2008-05-30 2008-05-30
US13053908P 2008-05-30 2008-05-30
US13039408P 2008-05-30 2008-05-30
PCT/US2009/045365 WO2009155015A1 (en) 2008-05-30 2009-05-28 Anti-flt3 antibodies

Publications (1)

Publication Number Publication Date
EA201071421A1 true EA201071421A1 (ru) 2011-08-30

Family

ID=41092183

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071421A EA201071421A1 (ru) 2008-05-30 2009-05-28 Анти-flt3 антитела

Country Status (18)

Country Link
US (3) US20110091470A1 (ru)
EP (1) EP2300500A1 (ru)
JP (1) JP2011521647A (ru)
KR (1) KR20110004455A (ru)
CN (1) CN102046659A (ru)
AR (1) AR071891A1 (ru)
AU (1) AU2009260517B2 (ru)
BR (1) BRPI0912173A2 (ru)
CA (1) CA2726522A1 (ru)
CL (1) CL2009001277A1 (ru)
EA (1) EA201071421A1 (ru)
IL (1) IL209142A0 (ru)
MX (1) MX2010013144A (ru)
NZ (1) NZ588791A (ru)
PE (1) PE20091963A1 (ru)
TW (1) TWI374032B (ru)
WO (1) WO2009155015A1 (ru)
ZA (1) ZA201008024B (ru)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
WO2011083124A1 (en) 2010-01-05 2011-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists for the treatment or the prevention of pain disorders
US20130156764A1 (en) * 2010-03-12 2013-06-20 The Johns Hopkins University Neutralization of flt3 ligand as a leukemia therapy
JO3625B1 (ar) * 2011-09-22 2020-08-27 Amgen Inc بروتينات رابطة للأنتيجين cd27l
US20150064203A1 (en) 2012-03-08 2015-03-05 Japan Science And Technology Agency Anticancer agent
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
AR103896A1 (es) * 2015-03-09 2017-06-14 Agensys Inc Conjugados de fármacos de anticuerpos (adc) anti-proteínas flt3
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
CA2999037A1 (en) * 2015-09-23 2017-03-30 Cytoimmune Therapeutics, LLC Flt3 directed car cells for immunotherapy
EP3380620B1 (en) 2015-11-23 2024-07-03 Novartis AG Optimized lentiviral transfer vectors and uses thereof
CN109072195A (zh) 2015-12-30 2018-12-21 诺华股份有限公司 具有增强功效的免疫效应细胞疗法
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
WO2017205747A1 (en) * 2016-05-27 2017-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
JP7062647B2 (ja) 2016-06-17 2022-05-06 マジェンタ セラピューティクス インコーポレイテッド Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
EP3559038B1 (en) * 2016-12-21 2022-12-14 The United States of America as represented by The Secretary Department of Health and Human Services Human monoclonal antibodies specific for flt3 and uses thereof
JP7256744B2 (ja) 2017-01-20 2023-04-12 マジェンタ セラピューティクス インコーポレイテッド Ｃｄ１３７＋細胞の枯渇のための組成物および方法
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
CN111093640A (zh) 2017-05-17 2020-05-01 国家健康与医学研究院 用于改善阿片类药物疼痛治疗的flt3抑制剂
PE20242042A1 (es) * 2017-06-02 2024-10-10 Pfizer Anticuerpos especificos para flt3 y sus usos
BR112019024604A2 (pt) * 2017-06-02 2020-06-23 Pfizer Inc. Receptores de antígenos quiméricos que alvejam flt3
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
AU2018309712A1 (en) * 2017-07-31 2020-02-13 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and FLT3
CA3078270A1 (en) 2017-10-25 2019-05-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
SG11202007945UA (en) 2018-02-20 2020-09-29 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
KR20210111785A (ko) * 2018-12-18 2021-09-13 베링거 잉겔하임 아이오 캐나다 인크. Flt3 항진제 항체 및 이의 용도
JP2022514315A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CA3136618A1 (en) * 2019-04-10 2020-10-15 Elevatebio Technologies, Inc. Flt3-specific chimeric antigen receptors and methods of using the same
TW202110873A (zh) 2019-04-30 2021-03-16 美商聖堤生物科技股份有限公司 嵌合受體及其使用方法
AU2020279974B2 (en) 2019-05-21 2024-12-19 Novartis Ag CD19 binding molecules and uses thereof
EP3976104A4 (en) * 2019-05-24 2023-10-04 Elixiron Immunotherapeutics (Hong Kong) Limited ANTI-CSF1R ANTIBODIES, IL10 FUSION PROTEINS AND THEIR USES
BR112022006817A2 (pt) * 2019-10-15 2022-07-05 Dragonfly Therapeutics Inc Anticorpos direcionados a flt3 e uso dos mesmos
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
KR20220144841A (ko) * 2020-02-21 2022-10-27 하푼 테라퓨틱스, 인크. Flt3 결합 단백질 및 사용 방법
JP7525109B2 (ja) 2020-03-18 2024-07-30 学校法人金沢医科大学 Ｃｄ１３５＋細胞を含む医薬組成物
CA3180188A1 (en) * 2020-04-14 2021-10-21 Les Laboratoires Serviers Anti-flt3 antibodies and compositions
AU2021256053A1 (en) 2020-04-17 2022-11-10 City Of Hope FLT3-targeted chimeric antigen receptor modified cells for treatment of FLT3-positive malignancies
EP4142749A1 (en) 2020-04-30 2023-03-08 The Regents of the University of Colorado, A Body Corporate Multispecific anti-flt3 chimeric antigen receptors
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
KR20230024967A (ko) 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
EP4168007A1 (en) 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN111808821B (zh) * 2020-06-24 2022-06-14 南方医科大学珠江医院 Flt3-nkg2d双靶点car-t的构建与制备
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2021378316A1 (en) 2020-11-13 2023-06-01 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022229853A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
WO2023023491A1 (en) * 2021-08-16 2023-02-23 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use
US12129302B2 (en) 2021-08-25 2024-10-29 Ibio, Inc. Anti-CD-25 antibody
US20250049939A1 (en) * 2021-12-10 2025-02-13 Tubulis Gmbh Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU1626588A (en) 1987-04-03 1988-11-02 Hermann Hofmann Process for composting organic material and device for carrying out this process
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5185438A (en) 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
US7537932B1 (en) * 1993-05-19 2009-05-26 Schering Corporation Antibodies that bind purified mammalian FLT3 ligands
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
DE69430313T2 (de) 1993-09-08 2002-08-08 Imclone Systems, Inc. Monoklonale antikörper, die flk-2-rezeptoren erkennen, und die isolierung primitiver hämatopoietischer stammzellpopulationen
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
DE19608769C1 (de) * 1996-03-07 1997-04-10 Univ Eberhard Karls Antikörper BV10A4H2
US6084060A (en) 1996-12-09 2000-07-04 Imclone Systems Incorporated Composition and method for preserving progenitor cells
DE19727814C1 (de) * 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
BR9910511A (pt) 1998-05-15 2001-11-20 Imclone Systems Inc Tratamento de tumores humanos com radiação einibidores de tirosina cinases receptoras de fatorde crescimento
US6999122B1 (en) * 1999-07-22 2006-02-14 Minolta Co., Ltd. Solid-state logarithmic image sensing device
ATE440869T1 (de) 2001-06-20 2009-09-15 Fibron Ltd Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon
JPWO2005094823A1 (ja) 2004-03-30 2007-08-16 協和醗酵工業株式会社 Ｆｌｔ−３阻害剤
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
CN103694351A (zh) 2007-06-05 2014-04-02 耶鲁大学 受体酪氨酸激酶抑制剂及其使用方法
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)

Also Published As

Publication number Publication date
MX2010013144A (es) 2010-12-21
JP2011521647A (ja) 2011-07-28
AU2009260517A1 (en) 2009-12-23
CA2726522A1 (en) 2009-12-23
PE20091963A1 (es) 2010-01-15
BRPI0912173A2 (pt) 2016-07-26
KR20110004455A (ko) 2011-01-13
EP2300500A1 (en) 2011-03-30
IL209142A0 (en) 2011-01-31
US20110091470A1 (en) 2011-04-21
WO2009155015A1 (en) 2009-12-23
NZ588791A (en) 2012-05-25
TW201010722A (en) 2010-03-16
AU2009260517B2 (en) 2012-12-06
CL2009001277A1 (es) 2010-10-08
US8071099B2 (en) 2011-12-06
US20110008355A1 (en) 2011-01-13
US20090297529A1 (en) 2009-12-03
AR071891A1 (es) 2010-07-21
CN102046659A (zh) 2011-05-04
TWI374032B (en) 2012-10-11
ZA201008024B (en) 2012-04-25

Similar Documents

Publication Publication Date Title
EA201071421A1 (ru) Анти-flt3 антитела
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201791393A3 (ru) Антитела к erbb3 и их применение
EA201100239A1 (ru) Композиции, одновалетные в отношении связывания cd28, и способы их применения
CY1118668T1 (el) Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
UA112434C2 (uk) Антигензв'язувальний білок, який специфічно зв'язується з всма
EA200870265A1 (ru) Функционально активные антитела
BRPI0607728A2 (pt) complexo de lipoproteìna carregado reconstituìdo, composição farmacêutica, e, uso de um complexo de lipoproteìna carregado
UA109633C2 (uk) Антитіло людини проти тканинного фактора
PE20090227A1 (es) Composiciones farmaceuticas que comprenden agentes anti-beta-klotho
MY165273A (en) Anti-cd48 antibodies and uses thereof
PH12015500576A1 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
ATE534752T1 (de) Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll)
EA201300978A1 (ru) Антитела к сеа
PL1830881T3 (pl) Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
MA32568B1 (fr) Formulations pharmaceutiques contenant des ligands de recepteur de dopamine
MX2011006725A (es) Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
EA201201623A1 (ru) Лечение диабета 2 типа
EP3988673A3 (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial